Why IMU is a multi multi bagger, page-25911

Christmas Day is the 25th December, we all are aware of this simple fact, knowing this we don't start saying in February when is Christmas?
Now, just because we don't have a definite end date for presentation of data from imugene we have this constant debate about when we will see it.
Trials take some time to set up and run, we have to run them according to FDA policies and other requirements, also to prepare to present data at key stages the trial is interrupted to investigate this data, have it peer reviewed and prepared for a conferences.
Trials are also very expensive and when running multiple trials (as imugene is), the dollars are racing out the door, Biotechs have to be strategic about every move they make to ensure best value for money.
Leslie Chong would be intrinsically aware that shareholders are concerned about the shareprice, but I ask what control does she have over this, no more than we do as shareholders.
A data cut would be taking place soon, if not currently for Oncarlytics and acer-cel, this will be early dat but should provide proof of concept in regards to the OASIS trial, and further endorsement of the acer-cel technology.
Safety is confirmed, we await some positive indications to show patients are getting extra time with their loved ones.
Our Christmas will come, in time, and when it does the gìft of giving will be our reward.

DYOR opinion only